Segmental Progressive Overgrowth with Fibroadipose Hyperplasia: A Patient Guide

Segmental Progressive Overgrowth—often presenting as Fibroadipose Overgrowth (FAO) or Fibroadipose Hyperplasia—is a rare condition characterized by the disproportionate growth of specific parts of the body. It belongs to a group of clinical phenotypes known as the PIK3CA-Related Overgrowth Spectrum (PROS), which all share a common genetic driver ^[1]. For patients and parents, this diagnosis often comes after months of observing asymmetry in a child’s limbs, torso, or digits, where fat and fibrous tissues grow more rapidly than the rest of the body ^[2]. While the physical changes can be striking, understanding the underlying science is the first step toward managing the condition effectively.

The root of this overgrowth is a “spelling error” in the PIK3CA gene, known as a postzygotic somatic mosaic mutation ^[3]. This means the genetic change usually occurred randomly in a single cell during early development in the womb, rather than being inherited from a parent. This specific mutation acts like a growth switch that is overstimulating a biological pathway that tells cells to divide and expand ^[4]. Because the mutation is mosaic, it only affects certain “segments” of the body, leading to the characteristic localized overgrowth of fatty (adipose) and tough (fibrous) tissue, though bone, muscle, nerves, and vascular structures can also be involved ^[1].

In addition to tissue overgrowth, individuals with this condition may develop vascular malformations, which are clusters of abnormally formed blood or lymph vessels ^[5]. These are typically “slow-flow” lesions that can cause the affected area to feel heavy, ache, or appear discolored. Because the overgrowth is progressive, it often changes as the person grows, which can lead to challenges with mobility, limb-length differences, and gait ^[6]. However, the timing and distribution vary, and growth can fluctuate, slow, or stabilize. Recognizing these signs early allows families to transition from the uncertainty of a “mystery illness” to a proactive, individualized management plan focused on preserving function and quality of life ^[7].

Modern care for PROS has shifted toward a coordinated, multidisciplinary approach that treats the whole patient rather than just the physical symptoms ^[8]. This team of specialists works together to balance traditional interventions, such as orthopedic monitoring and surgery, with newer targeted therapies like alpelisib, which aim to inhibit the downstream PI3K-alpha signaling pathway driven by the genetic cause ^[9]. While living with Segmental Progressive Overgrowth requires ongoing surveillance, the emergence of precision medicines and integrated care teams offers comprehensive, individualized support for families navigating this rare diagnosis ^[10].